Federal drug safety law may limit access to bevacizumab

CHICAGO – Recent federal drug safety legislation may affect patient access to bevacizumab, an expert said at a press briefing here.“[It was important to us] because of the implications that it has for access to pharmaceuticals, physician-administered pharmaceuticals in particular, and whether or not bevacizumab (Avastin, Genentech)  can stay in the marketplace as an off-label ophthalmic product,” Michael X. Repka, MD, American Academy of Ophthalmology medical director for governmental affairs, said.